• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations.

作者信息

Huang Lining, Wang Liang, Qiao Zhiming

机构信息

Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215004, China.

Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610000, Sichuan, China.

出版信息

Hepatol Int. 2025 Jun 17. doi: 10.1007/s12072-025-10853-z.

DOI:10.1007/s12072-025-10853-z
PMID:40526358
Abstract
摘要

相似文献

1
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations.肝脏免疫相关不良反应、免疫检查点抑制剂的持续使用与生存：除初步观察结果外还需有力证据
Hepatol Int. 2025 Jun 17. doi: 10.1007/s12072-025-10853-z.
2
Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗后免疫相关不良事件接受类固醇治疗的退伍军人的存活率。
JAMA Netw Open. 2023 Oct 2;6(10):e2340695. doi: 10.1001/jamanetworkopen.2023.40695.
3
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.在临床实践中，高度可变的时间使得免疫疗法的疗效和毒性成为彼此不切实际的生物标志物。
Front Immunol. 2024 Apr 16;15:1351739. doi: 10.3389/fimmu.2024.1351739. eCollection 2024.
4
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.泰国接受免疫检查点抑制剂治疗的实体瘤患者的免疫相关不良事件的模式和结局：一项多中心分析。
BMC Cancer. 2021 Nov 25;21(1):1275. doi: 10.1186/s12885-021-09003-z.
5
Safety of sequential immune checkpoint inhibitors after prior immune therapy.序贯免疫检查点抑制剂在既往免疫治疗后的安全性。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2375-2382. doi: 10.1007/s00432-022-04137-4. Epub 2022 Jun 21.
6
Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.晚期恶性肿瘤患者在对免疫检查点抑制剂产生继发性耐药和发生免疫相关不良事件时肠道微生物群的动态变化。
Front Oncol. 2023 Apr 11;13:1144534. doi: 10.3389/fonc.2023.1144534. eCollection 2023.
7
Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗后发生静脉血栓栓塞事件的癌症患者的特征和结局
Am J Clin Oncol. 2023 Mar 1;46(3):94-100. doi: 10.1097/COC.0000000000000981. Epub 2023 Feb 3.
8
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.癌症患者发生免疫相关不良反应后免疫检查点抑制剂的再次挑战
JAMA Oncol. 2020 Jun 1;6(6):865-871. doi: 10.1001/jamaoncol.2020.0726.
9
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.癌症患者因出现 ≥2 级免疫相关不良反应而停止使用免疫检查点抑制剂后再次使用的安全性。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001622.
10
Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.转移性非小细胞肺癌患者在疾病进展前提前停用免疫检查点抑制剂治疗：一项生存分析
Front Oncol. 2024 Jun 21;14:1417175. doi: 10.3389/fonc.2024.1417175. eCollection 2024.

引用本文的文献

1
Reply to Letter to the Editor "Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations".致编辑的信的回复：“肝脏免疫相关不良反应、免疫检查点抑制剂的继续使用与生存：除初步观察外还需要有力证据”
Hepatol Int. 2025 Jul 8. doi: 10.1007/s12072-025-10868-6.

本文引用的文献

1
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors.肝脏免疫相关不良事件提高了接受免疫检查点抑制剂治疗的恶性肿瘤患者的总生存率。
Hepatol Int. 2025 Apr 8. doi: 10.1007/s12072-025-10825-3.
2
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者严重免疫相关不良事件及结局的管理
Oncologist. 2024 Nov 20. doi: 10.1093/oncolo/oyae318.
3
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
接受免疫检查点抑制剂治疗的转移性尿路上皮癌患者因免疫相关不良事件需要治疗中断或停药的安全性和疗效结果。
Clin Genitourin Cancer. 2024 Apr;22(2):368-379. doi: 10.1016/j.clgc.2023.12.007. Epub 2023 Dec 15.
4
Microbiota-dependent activation of CD4 T cells induces CTLA-4 blockade-associated colitis via Fcγ receptors.菌群依赖的 CD4 T 细胞激活通过 Fcγ 受体诱导 CTLA-4 阻断相关结肠炎。
Science. 2024 Jan 5;383(6678):62-70. doi: 10.1126/science.adh8342. Epub 2024 Jan 4.
5
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.